| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9861b35d00c508fbdba6e1f56562d82e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C51-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-205 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-41 |
| filingDate |
2019-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eb1e7bb9eab02c5b1db4cd9b7371767 |
| publicationDate |
2020-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10639312-B1 |
| titleOfInvention |
Finished pharmaceutical dosage form of a methenamine salt such as methenamine mandelate |
| abstract |
The present invention contemplates a high dose finished pharmaceutical dosage form comprising a methenamine salt, such as methenamine mandelate, as an active pharmaceutical ingredient wherein the methenamine salt API has a moisture content that is less than the upper limit specified in the USP. A preferred embodiment of the present invention has a moisture content that is half of the limit set forth in the USP for each particular methenamine salt. An even more preferred embodiment has a moisture content of less than or equal to one-tenth of a percent (0.1%), regardless of the methenamine salt. The present invention may include one or more pharmaceutically acceptable ingredients. The present invention also contemplates a moisture content of the high dose finished pharmaceutical dosage form that is less than one percent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021322424-A1 |
| priorityDate |
2019-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |